 Shares of ChemoCentryx Inc. CCXI, 5.43 soared 80.3 in premarket trading on Friday after the company said that it had received approval from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The company said this is the first new drug to treat the rare autoimmune disease in a decade. 